AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2654350 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (free alpha-tocopherol) administered for greater than or equal to 8 days
Number of subjects: 755
Study 2654350 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (free alpha-tocopherol)
Number of subjects: 755
Study 901851 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Group
Number of subjects: 40
Study 901851 — intervention group
Group type: COMPARATOR
Intervention: Pleasant Group
Number of subjects: 40
Study 30701691 — intervention group
Group type: EXPERIMENTAL
Intervention: VF biofeedback
Number of subjects: 19
Study 30701691 — intervention group
Group type: COMPARATOR
Intervention: ssEMG biofeedback
Number of subjects: 19
Study 30701691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed biofeedback (VF phase 1, ssEMG phase 2)
Number of subjects: 19
Study 28729151 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose pembrolizumab (2 mg/kg) plus reduced-dose ipilimumab (1 mg/kg) every 3 weeks for four doses, followed by pembrolizumab (2 mg/kg) every 3 weeks for up to 2 years or until disease progression or intolerable toxicity.
Number of subjects: 153
Study 28729151 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose pembrolizumab plus reduced-dose ipilimumab
Number of subjects: 153
Study 25671796 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH eating plan plus physical activity
Number of subjects: 85
Study 25671796 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 23822902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 0.4 M
Number of subjects: 4
Study 23822902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 0.8 M
Number of subjects: 4
Study 23822902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 1.2 M
Number of subjects: 4
Study 23822902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerne hay cubes at 1.6 M
Number of subjects: 4
Study 23822902 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy recovery including heat production at varying DMI levels
Number of subjects: 4
Study 21858972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative anastomotic air testing
Number of subjects: 60
Study 21858972 — intervention group
Group type: COMPARATOR
Intervention: Control group without air testing
Number of subjects: 60
Study 19833688 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sampling kit for partner notification arm
Number of subjects: 200
Study 19833688 — intervention group
Group type: COMPARATOR
Intervention: Contact slips (swab testing arm)
Number of subjects: 200
Study 17112806 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on the first day and 200 mg twice on the second day)
Number of subjects: 12
Study 17112806 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg once daily for 3 days)
Number of subjects: 12
Study 17112806 — intervention group
Group type: COMPARATOR
Intervention: Control (20 microg/kg intravenous alfentanil without pretreatment)
Number of subjects: 12
Study 15253849 — intervention group
Group type: EXPERIMENTAL
Intervention: Real qi therapy
Number of subjects: 36
Study 15253849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11743061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-plus-exercise program
Number of subjects: 264
Study 11743061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-only program
Number of subjects: 264
Study 11743061 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 264
Study 9225710 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 1
Study 9225710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 8477560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg moxisylyte
Number of subjects: 20
Study 8477560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg moxisylyte
Number of subjects: 20
Study 8477560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg moxisylyte
Number of subjects: 20
Study 8477560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3307093 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropins (HCG, 5,000 IU I.M. twice per week)
Number of subjects: 45
Study 3307093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30950703 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-lift exercise (HLE)
Number of subjects: 27
Study 30950703 — intervention group
Group type: EXPERIMENTAL
Intervention: Recline exercise (RE)
Number of subjects: 27
Study 30950703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HLE and RE
Number of subjects: 27
Study 30572894 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g krill oil powder
Number of subjects: 35
Study 30572894 — intervention group
Group type: COMPARATOR
Intervention: 4 g placebo
Number of subjects: 35
Study 27855089 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling (arm A)
Number of subjects: 834
Study 27855089 — intervention group
Group type: COMPARATOR
Intervention: Papanicolaou (Pap) testing (arm B)
Number of subjects: 834
Study 25124503 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement in children's anxiety treatment
Number of subjects: 54
Study 25124503 — intervention group
Group type: COMPARATOR
Intervention: Non-involved mothers
Number of subjects: 54
Study 25124503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (involved and not involved)
Number of subjects: 54
Study 25124503 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported parental efficacy and observed negativity
Number of subjects: 54
Study 21905086 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine 4 mg long‐acting (LA)
Number of subjects: 20
Study 21905086 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 19452332 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical method (Carisolv)
Number of subjects: 120
Study 19452332 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary instruments
Number of subjects: 120
Study 19452332 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 120
Study 17092965 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + placebo
Number of subjects: 16
Study 17092965 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + pindolol 10 mg
Number of subjects: 16
Study 17092965 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + ketanserin 50 mg
Number of subjects: 16
Study 17092965 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 15642064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) mouth rinse for 15 seconds
Number of subjects: 90
Study 15642064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) mouth rinse for 30 seconds
Number of subjects: 90
Study 15642064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) mouth rinse for 60 seconds
Number of subjects: 90
Study 15642064 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 12552952 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 5-FU for 5 days at a dose of 320 mg/m2 (CIV group, n = 6)
Number of subjects: 30
Study 12552952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus intravenous injection of 5-FU for 5 days at a dose of 320 mg/m2 (bolus group, n = 8)
Number of subjects: 30
Study 12552952 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (n = 16)
Number of subjects: 30
Study 12552952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU-resistant group
Number of subjects: 30
Study 12552952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU-sensitive group
Number of subjects: 30
Study 9585021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT) screening
Number of subjects: 3
Study 7815748 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO 6,000 IU, subcutaneously once a week for up to 9 weeks (group I)
Number of subjects: 30
Study 7815748 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO 9,000 IU, subcutaneously once a week for up to 9 weeks (group II)
Number of subjects: 30
Study 7815748 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (both groups)
Number of subjects: 30
Study 7815748 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 2576666 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg once daily
Number of subjects: 43
Study 2576666 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 43
Study 1059499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and thioguanine
Number of subjects: 326
Study 1059499 — intervention group
Group type: COMPARATOR
Intervention: Cytosine arabinoside alone
Number of subjects: 326
Study 31227287 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 118
Study 31227287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 26215773 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinflation after early release of tourniquet
Number of subjects: 206
Study 26215773 — intervention group
Group type: COMPARATOR
Intervention: Early release (deflation) group
Number of subjects: 206
Study 25306520 — intervention group
Group type: EXPERIMENTAL
Intervention: Silbroncho (silicon DLTs)
Number of subjects: 60
Study 25306520 — intervention group
Group type: COMPARATOR
Intervention: Broncho‐Cath (PVC DLTs)
Number of subjects: 60
Study 25306520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 23788085 — intervention group
Group type: EXPERIMENTAL
Intervention: pPCI
Number of subjects: 95
Study 22926838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin
Number of subjects: 172
Study 22926838 — intervention group
Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 172
Study 19927695 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps-In-Noise (GIN) test
Number of subjects: 72
Study 17851827 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride gel (4000 ppm F)
Number of subjects: 135
Study 17851827 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 135
Study 15333056 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational mailers (2 packets mailed approximately 3 months apart)
Number of subjects: 312
Study 15333056 — intervention group
Group type: COMPARATOR
Intervention: Usual care for hypertension
Number of subjects: 312
Study 16208800 — intervention group
Group type: EXPERIMENTAL
Intervention: PC 7000 toothbrush (Oral‐B ProfessionalCare 7000)
Number of subjects: 92
Study 16208800 — intervention group
Group type: COMPARATOR
Intervention: SBP toothbrush (Crest SpinBrush Pro)
Number of subjects: 92
Study 16208800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 92
Study 16208800 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety examinations
Number of subjects: 92
Study 10695793 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg once a day for 3 days
Number of subjects: 113
Study 10695793 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole 50 mg/kg single dose
Number of subjects: 113
Study 8670601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ) 2.0 g/day
Number of subjects: 120
Study 8670601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 1662583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer with 99mTc‐labelled colloidal human serum albumin (0.05 mg, 37 MBq)
Number of subjects: 9
Study 1662583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer with increased 99mTc activity (92 MBq)
Number of subjects: 9
Study 1662583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer particle size measurement
Number of subjects: 9
Study 1662583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer mass and radionuclide output measurement
Number of subjects: 9
Study 6751018 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 6751018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31718728 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 50
Study 31718728 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 50
Study 29103368 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIP implementation intervention
Number of subjects: 0
Study 29103368 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 26911887 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV with additional tin filtration, 150mAs, 192x0.6-mm slice collimation
Number of subjects: 129
Study 26911887 — intervention group
Group type: COMPARATOR
Intervention: Standard low-dose protocol (100 kV, 50mAs, 128×0.6-mm slice collimation)
Number of subjects: 129
Study 26911887 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV with additional tin filtration
Number of subjects: 129
Study 26911887 — intervention group
Group type: COMPARATOR
Intervention: Standard low-dose protocol
Number of subjects: 129
Study 25440004 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 117
Study 25440004 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation supraglottic airway devices (SADs)
Number of subjects: 117
Study 25440004 — intervention group
Group type: COMPARATOR
Intervention: First-generation SAD
Number of subjects: 117
Study 25440004 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway unique
Number of subjects: 117
Study 25440004 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction disposable
Number of subjects: 117
Study 25440004 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme laryngeal mask airway (SLMA)
Number of subjects: 117
Study 22137378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate therapy (AT) with meropenem or meropenem plus ciprofloxacin
Number of subjects: 739
Study 22137378 — intervention group
Group type: COMPARATOR
Intervention: Inadequate therapy (IT)
Number of subjects: 739
Study 20147300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (RMS)
Number of subjects: 400
Study 20147300 — intervention group
Group type: COMPARATOR
Intervention: Custom Spectacles (CS)
Number of subjects: 400
Study 18589019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with free virgin olive oil (1 L/week)
Number of subjects: 1551
Study 18589019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with free mixed nuts (30 g/day)
Number of subjects: 1551
Study 18589019 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal instructions and leaflet recommending National Cholesterol Education Program Adult Treatment Panel III dietary guidelines)
Number of subjects: 1551
Study 15802772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone, MK‐4) 45 mg/day
Number of subjects: 0
Study 15802772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone, MK‐4)
Number of subjects: 0
Study 12575213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg once daily intravenous drip)
Number of subjects: 119
Study 12575213 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg twice daily intravenous drip)
Number of subjects: 119
Study 14528551 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and written information provided prior to the PHE
Number of subjects: 100
Study 14528551 — intervention group
Group type: COMPARATOR
Intervention: Verbal and written information provided following the second interview
Number of subjects: 100
Study 8599587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking soda-hydrogen peroxide dentifrice (Mentadent)
Number of subjects: 25
Study 8599587 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (Crest)
Number of subjects: 25
Study 31912800 — intervention group
Group type: EXPERIMENTAL
Intervention: Istiratumab (2.8 g intravenously every 2 weeks)
Number of subjects: 88
Study 31912800 — intervention group
Group type: COMPARATOR
Intervention: Nab-paclitaxel and gemcitabine (control)
Number of subjects: 88
Study 31912800 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both arms)
Number of subjects: 88
Study 30894210 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-LED-RL phototherapy at doses of 480 J/cm2 and 640 J/cm2
Number of subjects: 60
Study 30894210 — intervention group
Group type: COMPARATOR
Intervention: Mock therapy
Number of subjects: 60
Study 27760887 — intervention group
Group type: EXPERIMENTAL
Intervention: iRest® meditation
Number of subjects: 29
Study 27760887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dreampad Pillow®
Number of subjects: 29
Study 27760887 — intervention group
Group type: COMPARATOR
Intervention: sleep hygiene
Number of subjects: 29
Study 25348834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided group
Number of subjects: 110
Study 25348834 — intervention group
Group type: COMPARATOR
Intervention: Palpation group
Number of subjects: 110
Study 25348834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 23673688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 36
Study 23673688 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic calculator
Number of subjects: 36
Study 23673688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen and paper
Number of subjects: 36
Study 22094316 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rehydration (60 mL/kg) with 0.9% saline over an hour
Number of subjects: 226
Study 22094316 — intervention group
Group type: COMPARATOR
Intervention: Standard rehydration (20 mL/kg) with 0.9% saline over an hour
Number of subjects: 226
Study 22094316 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rehydration
Number of subjects: 226
Study 22094316 — intervention group
Group type: COMPARATOR
Intervention: Standard rehydration
Number of subjects: 226
Study 19015353 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of elvucitabine
Number of subjects: 30
Study 19015353 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of ritonavir
Number of subjects: 30
Study 19015353 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of elvucitabine coadministered with 300 mg of ritonavir
Number of subjects: 30
Study 19015353 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 16886929 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA) patients
Number of subjects: 471
Study 16886929 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura (MoA) patients
Number of subjects: 471
Study 16886929 — intervention group
Group type: COMPARATOR
Intervention: Young stroke patients
Number of subjects: 471
Study 16886929 — intervention group
Group type: COMPARATOR
Intervention: Elderly stroke patients
Number of subjects: 471
Study 16886929 — intervention group
Group type: COMPARATOR
Intervention: Cryptogenic stroke in young patients
Number of subjects: 471
Study 16886929 — intervention group
Group type: COMPARATOR
Intervention: Cryptogenic stroke in elderly patients
Number of subjects: 471
Study 14984149 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA
Number of subjects: 39
Study 14984149 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 39
Study 14984149 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 39
Study 14728013 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 9413102 — intervention group
Group type: EXPERIMENTAL
Intervention: Td + full strength acellular pertussis vaccine (PT, 1 microgram/0.5 ml; FHA, 4 micrograms/0.5 ml)
Number of subjects: 80
Study 9413102 — intervention group
Group type: EXPERIMENTAL
Intervention: Td + half strength acellular pertussis vaccine
Number of subjects: 80
Study 9413102 — intervention group
Group type: COMPARATOR
Intervention: Td alone
Number of subjects: 80
Study 8480701 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH therapy (experimental group, n = 18)
Number of subjects: 29
Study 8480701 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 29
Study 3119959 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH (25 micrograms)
Number of subjects: 25
Study 3119959 — intervention group
Group type: COMPARATOR
Intervention: TRH (200 micrograms)
Number of subjects: 25
Study 31109255 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Body Image Program (online platform for screening and delivering tailored feedback and interventions)
Number of subjects: 61
Study 31109255 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for treatment
Number of subjects: 61
Study 31109255 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for seeking treatment
Number of subjects: 61
Study 31109255 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to treatment
Number of subjects: 61
Study 31666270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (15 mg/kg initially, followed by 7.5 mg/kg every 6 hours for 5 days)
Number of subjects: 100
Study 31666270 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5% dextrose (every 6 hours for 5 days)
Number of subjects: 100
Study 31666270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 100
Study 29171485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (2nd group)
Number of subjects: 60
Study 29171485 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative metabolic‐mediated cerebroprotection (1st group)
Number of subjects: 60
Study 26619943 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary food given to underweight children
Number of subjects: 0
Study 26619943 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets targeted to undernutritioned children
Number of subjects: 0
Study 26619943 — intervention group
Group type: COMPARATOR
Intervention: Baseline bed net coverage at 20%
Number of subjects: 0